CNS Update: Clinical Studies Evaluating the Beneficial Efficacy of Escitalopram: A Step towards Development


eMediNexus    19 February 2023

Major depression is described as a debilitating, occasionally fatal disorder that may worsen the quality of life and well-being. 


Escitalopram has established a highly selective and dose-dependent inhibitory activity on human serotonin transport. Selective serotonin reuptake inhibitors (SSRIs) are approved to be the first-line drugs for managing major depressive disorder (MDD).


A recent study explored the therapeutic potential of escitalopram in managing MDD and panic disorders by exploring the data of many reputed databases.


The results underscored the clinical efficacy, safety, recent development, increased bioavailability profile and stable formulation of escitalopram. Clinical and pharmacoeconomic data proved escitalopram to be an effective first-line treatment option for MDD patients.


These results regarding escitalopram are encouraging for further research perspectives.


Source:  CNS & Neurological Disorders - Drug Targets, April 8, 2022.  DOI: https://doi.org/10.2174/1871527321666220301122807

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.